BioCentury | Jun 13, 2005
Clinical News

Oxford BioMedica preclinical data

...repair across the injury and significantly improved functional ability compared with placebo. Innurex delivers the retinoic acid receptor (RAR) beta 2...
BioCentury | Jun 7, 2004
Clinical News

Oxford BioMedica preclinical data

...in damaged limbs in a rat model of avulsion injury. Innurex is a lentivector delivering retinoic acid receptor (RAR) beta 2...
BioCentury | Dec 17, 2001
Company News

Oxford BioMedica, King’s College deal

...the college’s second investment in OXB. Under a February deal, OXB exclusively licensed the college’s retinoic acid receptor (RAR) beta 2...
BioCentury | Feb 12, 2001
Finance

Ebb & Flow

...BioMedica (LSE:OXB) gained 6.5p to 81.5p on obtaining a license from King's College to the retinoic acid receptor (RAR) beta 2...
BioCentury | Feb 12, 2001
Company News

Oxford BioMedica, King's College deal

...OXB exclusively licensed retinoic acid receptor (RAR) beta 2 , a gene associated with nerve regeneration, from the college. OXB said...
BioCentury | Feb 5, 2001
Company News

OXB acquires RAR beta 2 gene

...Oxford BioMedica (LSE:OXB) licensed from King's College (London, U.K.) the retinoic acid receptor (RAR) beta 2 gene, which is associated with...
Items per page:
1 - 6 of 6